

**PNEUMOCOCCAL VACCINE (PCV 10)**

<b>Trade Name</b>	Synflorix ®, (Glaxo Smith Kline)
<b>Class</b>	Vaccine
<b>Mechanism of Action</b>	<p>This vaccine has been formulated by joining polysaccharides (strings of sugars) from the outer coating of 10 bacteria known to most commonly cause pneumococcal disease in children, on to carrier proteins- (Protein D a non transferable surface protein from Haemophilus influenza, Diphtheria toxoid carrier protein and Tetanus toxoid carrier protein).</p> <p>Each 0.5mL dose of Synflorix contains:</p> <ul style="list-style-type: none"> <li>• 1 microgram of Pneumococcal polysaccharide serotypes 1*, 5*, 6B*, 7F*, 9V*, 14* and 23F* and</li> <li>• 3 micrograms of Pneumococcal polysaccharide serotypes 4*, 18C† and 19F#</li> </ul> <p>*conjugated to Protein D # conjugated to diphtheria toxoid carrier protein † conjugated to tetanus toxoid carrier protein.</p>
<b>Indications</b>	<p>Synflorix® is included in the NZ National Immunisation Schedule</p> <p>Helps prevent Strep pneumoniae infections such as bacteraemia, meningitis, pneumonia, otitis media and sinusitis.</p> <p>The 10 serotypes included in this vaccine represent the major disease causing serotypes in countries worldwide covering approximately 50 - 96% of cases of invasive pneumococcal disease in children under 5 years of age.</p> <p><b>If the baby is High Risk then refer to Prevenar 13 profile and note that Prevenar is given at 6wks, 3mths and 5mths:</b></p> <p><b>High Risk Criteria:</b></p> <ul style="list-style-type: none"> <li>• &lt;28 weeks gestation</li> <li>• Chronic lung disease</li> <li>• Cardiac disease with cyanosis or failure</li> <li>• Down Syndrome</li> <li>• Renal failure or Nephrotic syndrome</li> <li>• Intracranial shunts</li> <li>• Primary immune deficiency / HIV</li> <li>• Asplenia (anatomical or functional)</li> </ul>
<b>Contraindications</b>	<p>Hypersensitivity to any components of the vaccine.</p> <p>The occurrence of an allergic or anaphylactoid reaction following prior administration of Synflorix®</p> <p>Avoid intravenous, subcutaneous or intradermal administration</p> <p>Temperature ≥ 38 degrees Celsius</p>
<b>Supplied As</b>	Synflorix® is a white opaque suspension for injection and is supplied in 0.5mL prefilled syringes.

<b>Dilution</b>	N/A
<b>Dosage</b>	0.5mL
<b>Interval</b>	Synflorix® is included in the NZ National Immunisation Schedule and should be given at <b>6 weeks (day 42) and 5 months (22 weeks, day 151)</b>
<b>Administration</b>	Intramuscular injection into the anterolateral thigh.
<b>Compatible With</b>	Can be given with other routine childhood vaccinations but should be administered at a separate site. Do not mix in the same syringe as any other vaccine or medication. <b>Different injectable vaccines should always be given at different injection sites.</b>
<b>Incompatible With</b>	Synflorix® must not be mixed with any other medication.
<b>Interactions</b>	N/A
<b>Monitoring</b>	Close observation for 20 minutes post vaccination. Respiratory monitoring for 48hr with an apnea monitor (unless they are already receiving cardiorespiratory monitoring) when administering the primary immunisation series.
<b>Stability</b>	Manufacturers expiry, single use only, discard immediately after use, does not contain preservative.
<b>Storage</b>	Store at 2°C - 8°C (refrigerate, do not freeze) To protect the “cold chain” vaccines are no longer kept as stock in ward fridges and should be ordered from pharmacy as required.
<b>Adverse Reactions</b>	Common (>10%): pain, swelling and redness at injection site, irritability, fever, drowsiness, loss of appetite, Uncommon(1-10%): nausea, vomiting, Rare (<1%): seizures, rash, dyspnoea, allergy.
<b>Metabolism</b>	N/A
<b>Comments</b>	Due to lack of studies there is no clear guideline regarding the interchange ability of pneumococcal vaccine brands. There are TWO different pneumococcal vaccines currently registered for use in NZ (Prevenar® PCV13 and Synflorix PCV10) and each has a slightly different schedule for administration. Please check the profile(s) carefully to ensure the appropriate formulation and dosing schedule is prescribed and administered.
<b>References</b>	1. <a href="http://www.medsafe.govt.nz/prof/datasheet">www.medsafe.govt.nz/prof/datasheet</a> 2. <a href="http://www.immune.org.nz">www.immune.org.nz</a> 3. BNF for Children 2010-2011

<b>Updated By</b>	A Lynn, B Robertshawe July 2011, Dec 2012 (re-order profile) A Lynn, B Robertshawe July 2017 reintroduced into schedule A Lynn October 2018 – clarify days for 3 and 5 months A Lynn Aug 2020 – no dose at 3 mths from 1.7.20
-------------------	--